Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Healthcare Biotechnology
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by lv_426on Mar 12, 2020 8:49pm
71 Views
Post# 30802059

RE:RE:RE:RE:Shiseido is sticking with RCH-01

RE:RE:RE:RE:Shiseido is sticking with RCH-01
Ingiboy wrote:
Genie29j wrote:

There isn't any need for Shiseido to mention how they are going to get there and with what tools/technologies. It just matters that things are progressing forward. it's implied that RepliCel remains as strategic partner 

i would also imagine that it would be highly unethical for RepliCel to make a false statement as such. This is moving forward and RepliCel is still one of the leading technologies to get them to the finish line 



Genie don't delude yourself.  These two companes are not collaborating at this point.  Hopefully in the future they will but not at the moment.  Trust me, if they were working together their would be a shout out to the origfinal technology provided by Replicel (RCH-01).



I agree. They would have put out a joint press release. Replicel is just piggie backing shiseido's news...for now
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities